Your browser is no longer supported. Please, upgrade your browser.
Settings
MRNS Marinus Pharmaceuticals, Inc. daily Stock Chart
MRNS [NASD]
Marinus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.11 Insider Own7.92% Shs Outstand25.51M Perf Week13.12%
Market Cap109.95M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float24.01M Perf Month55.04%
Income-22.50M PEG- EPS next Q-0.17 Inst Own41.30% Short Float6.40% Perf Quarter212.32%
Sales- P/S- EPS this Y11.80% Inst Trans1.75% Short Ratio1.15 Perf Half Y197.24%
Book/sh0.74 P/B5.82 EPS next Y24.30% ROA-75.50% Target Price11.00 Perf Year138.12%
Cash/sh0.79 P/C5.44 EPS next 5Y- ROE-107.40% 52W Range0.82 - 5.44 Perf YTD326.73%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-20.77% Beta-
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low424.78% ATR0.38
Employees14 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)79.33 Volatility8.09% 8.89%
OptionableNo Debt/Eq0.21 EPS Q/Q54.90% Profit Margin- Rel Volume1.29 Prev Close4.30
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume1.34M Price4.31
Recom2.00 SMA2032.01% SMA5072.16% SMA200170.44% Volume1,730,815 Change0.23%
Aug-10-16Reiterated Jefferies Buy $2.50 → $3
Jun-14-16Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-08-16Reiterated Stifel Buy $23 → $16
Dec-17-15Initiated RBC Capital Mkts Outperform $14
Nov-17-15Initiated Jefferies Buy $14
Oct-30-15Reiterated Oppenheimer Outperform $21 → $17
Aug-05-15Reiterated Oppenheimer Outperform $12 → $21
Sep-19-17 04:01PM  Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriters option to purchase additional shares GlobeNewswire
Sep-15-17 07:30AM  Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Sep-14-17 04:01PM  Marinus Pharmaceuticals Announces Public Offering of Common Stock GlobeNewswire
Sep-12-17 11:42AM  Marinus Stock Surges on Successful Phase II Epilepsy Study Zacks -8.19%
08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Teva Pharmaceutical Industries ACCESSWIRE
Sep-11-17 10:35AM  Marinus Pharma Wins Big With Mid-Stage Epilepsy Study 24/7 Wall St. +33.01%
07:30AM  Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone GlobeNewswire
Aug-15-17 08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and CEL-SCI Corporation ACCESSWIRE
Aug-03-17 08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Sparks Therapeutics ACCESSWIRE
Aug-01-17 09:32PM  Marinus Pharmaceuticals posts 2Q loss Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results GlobeNewswire
Jun-30-17 10:57AM  Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US Zacks -5.52%
08:00AM  Today's Research Reports on Stocks to Watch: Inpixon and Marinus Pharmaceuticals Accesswire
Jun-29-17 02:29PM  FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder GlobeNewswire
Jun-27-17 07:30AM  Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression GlobeNewswire
May-01-17 07:36AM  Marinus Pharmaceuticals posts 1Q loss Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-18-17 07:30AM  Marinus to present Ganaxolone DATA at American academy of neurology annual meeting GlobeNewswire
Apr-11-17 07:30AM  Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer GlobeNewswire
Apr-10-17 07:30AM  Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference GlobeNewswire
Apr-05-17 09:00AM  Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone Business Wire
09:00AM  Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone
Mar-23-17 08:43AM  Ultragenyxs Seizure Drug Fails Study Investopedia
08:43AM  Ultragenyxs Seizure Drug Fails Study at Investopedia
Mar-22-17 04:16PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a +5.52%
Mar-16-17 01:04PM  MARINUS PHARMACEUTICALS INC Financials
Mar-15-17 07:30AM  Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference GlobeNewswire
Mar-13-17 07:35AM  MARINUS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report +8.97%
07:30AM  Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results GlobeNewswire
Feb-14-17 07:30AM  Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model GlobeNewswire
Feb-01-17 04:07PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
07:30AM  Marinus Appoints Michael R. Dougherty to its Board of Directors GlobeNewswire
Jan-24-17 08:20AM  Marinus Releases Positive Preliminary Data from CDKL5 Study Zacks
08:20AM  Marinus Releases Positive Preliminary Data from CDKL5 Study
07:20AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jan-23-17 03:42PM  Why This Seizure Drug Matters So Much for Marinus Pharma 24/7 Wall St. +18.10%
03:42PM  Why This Seizure Drug Matters So Much for Marinus Pharma
11:20AM  Marinus Anti-Seizure Drug Did Well in Early Trial Investopedia
11:20AM  Marinus Anti-Seizure Drug Did Well in Early Trial at Investopedia
10:57AM  Marinus Pharma stock surges 49% on positive mid-stage data for pediatric epilepsy drug at MarketWatch
07:30AM  Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder GlobeNewswire
Jan-19-17 05:16PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-09-17 06:09AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +11.89%
Jan-05-17 07:30AM  Marinus Provides Business Outlook for 2017 GlobeNewswire
Jan-03-17 10:40AM  Main Line biopharm firm gets a boost from the FDA at bizjournals.com
07:30AM  Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome GlobeNewswire
Nov-21-16 04:04PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
Nov-17-16 12:21PM  5 Stocks Under $10 Poised for Big Breakouts
Nov-15-16 07:30AM  Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus GlobeNewswire
Nov-08-16 04:40PM  MARINUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Nov-03-16 08:02AM  Marinus Pharmaceuticals posts 3Q loss -7.08%
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results GlobeNewswire
Oct-24-16 06:04AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Oct-19-16 09:54AM  Heres Why Investors Are Watching Sangamo Biosciences, GNC Holdings, and Three Other Stocks Today at Insider Monkey +5.76%
07:30AM  Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus GlobeNewswire
Oct-11-16 11:44AM  Marinus Pharmaceuticals, Inc. to Present at The MicroCap Conference on October 24-25 in Philadelphia Accesswire
Oct-03-16 06:09AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-29-16 09:00AM  Ganaxolone Reduces Seizures in Females with PCDH19 Pediatric Epilepsy GlobeNewswire -26.74%
Sep-23-16 01:45PM  Why These 5 Stocks Are Winning Today at Insider Monkey +26.14%
Sep-07-16 04:06PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,
07:30AM  Marinus Appoints Seth H.Z. Fischer to its Board of Directors GlobeNewswire
Aug-09-16 07:47PM  Marinus Pharmaceuticals posts 2Q loss
04:35PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:17PM  MARINUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
04:15PM  Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results GlobeNewswire
Jul-13-16 12:08PM  Cheap Stocks: These Aren't Necessarily a Lucky 7 +13.55%
07:17AM  7 Stocks Under $10 That Could Make You a Lot of Money
Jun-28-16 10:37AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:30AM  Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome GlobeNewswire
Jun-27-16 04:05PM  Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28 GlobeNewswire -7.46%
Jun-22-16 07:30AM  Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV GlobeNewswire
Jun-19-16 10:15AM  6 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Jun-14-16 09:46AM  Marinus Stock Down on Dismal Phase III Data on Ganaxolone -11.73%
06:05AM  Marinus Pharmaceuticals downgraded by RBC Capital Mkts
Jun-13-16 01:40PM  5 Stocks That Have Kicked Off the Week on a Sour Note at Insider Monkey -69.66%
12:39PM  Radnor biopharm's stock plunges following disappointing seizure treatment study at bizjournals.com
10:51AM  Stocks Seesaw as 'Brexit' Fears, Fed Feed Nerves
09:50AM  Why Marinus Pharmaceuticals Shares Are Sliding at 24/7 Wall St.
08:47AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:47AM  Stock Futures Slide; Microsoft to Buy LinkedIn
08:04AM  Marinus Pharma's trial of treatment for drug-resistant epilepsy failed to meet goals at MarketWatch
07:48AM  Marinus' drug for focal onset seizures fails in late-stage study
07:30AM  Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures GlobeNewswire
Jun-08-16 06:02PM  Marinus Pharmaceuticals, Inc. :MRNS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016
May-03-16 07:30AM  Marinus Pharmaceuticals to Participate in Bank of America Merrill Lynch Healthcare Conference GlobeNewswire +9.23%
May-02-16 05:34PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
05:26PM  MARINUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
07:40AM  Marinus Pharmaceuticals posts 1Q loss
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results GlobeNewswire
Apr-21-16 04:54PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Apr-19-16 07:30AM  Marinus Pharmaceuticals Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus GlobeNewswire
Apr-17-16 07:49AM  8 Stocks Under $10 to Trade for Big Gains at TheStreet
Apr-15-16 07:30AM  Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus GlobeNewswire +8.70%
Apr-12-16 07:30AM  Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting GlobeNewswire +6.75%
Mar-24-16 10:50AM  These 5 Under-$10 Stocks Are Set to Soar Higher at TheStreet +6.10%
Mar-07-16 05:23PM  MARINUS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report +23.44%
07:47AM  Marinus Pharmaceuticals posts 4Q loss
07:30AM  Marinus Pharmaceuticals Provides Business Update and 2015 Financial Results GlobeNewswire
Mar-01-16 12:59PM  The Stock Picks of This Obscure Hedge Fund Returned 70.5% In 2015; See What Its Betting On in 2016 at Insider Monkey
07:30AM  Marinus Pharmaceuticals to Present at the Cowen & Company Annual Healthcare Conference GlobeNewswire
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mehra Anand10% OwnerOct 20Sale1.39750,6831,042,69915,470Oct 24 04:49 PM